<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01544673</url>
  </required_header>
  <id_info>
    <org_study_id>A5951164</org_study_id>
    <nct_id>NCT01544673</nct_id>
  </id_info>
  <brief_title>Effect of Linezolid on Ex Vivo Neutrophil and Monocyte Function in Healthy Males</brief_title>
  <official_title>An Open-label, Placebo-controlled Phase 1 Study to Evaluate the Effect of Linezolid on Ex Vivo Neutrophil and Monocyte Function in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Results from previous studies have been inconclusive and the effect of linezolid on cytokines
      remains unclear. This study is designed to evaluate the effect of linezolid on the
      functionality of white blood cells (neutrophils and monocytes) in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in phagocytosis of gram-negative bacteria by neutrophils</measure>
    <time_frame>Baseline, day 4 and day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in phagocytosis of gram-negative bacteria by monocytes</measure>
    <time_frame>Baseline, day 4 and day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in interleukin-1 receptor antagonist secretion in response to lipopolysaccharide stimulation</measure>
    <time_frame>Baseline, day 4 and day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in interleukin-1-beta secretion in response to lipopolysaccharide stimulation</measure>
    <time_frame>Baseline, day 4 and day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in interleukin-6 secretion in response to lipopolysaccharide stimulation</measure>
    <time_frame>Baseline, day 4 and day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in interleukin-8 secretion in response to lipopolysaccharide stimulation</measure>
    <time_frame>Baseline, day 4 and day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in tumor necrosis factor alpha secretion in response to lipopolysaccharide stimulation</measure>
    <time_frame>Baseline, day 4 and day 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Linezolid peak concentration on day 4</measure>
    <time_frame>day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linezolid peak concentration on day 5</measure>
    <time_frame>day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linezolid trough concentration on day 5</measure>
    <time_frame>day 5</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Gram Positive Infection</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linezolid</intervention_name>
    <description>600 mg oral tablet twice daily for 4.5 days</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Zyvox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>500 mg oral placebo twice daily for 4.5 days</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects between the ages of 20 and 45 years, inclusive (Healthy is
             defined as no clinically relevant abnormalities identified by a detailed medical
             history, full physical examination, including blood pressure and pulse rate
             measurement and clinical laboratory tests).

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs).

        Exclusion Criteria:

          -  Any condition possibly affecting drug absorption (eg, gastrectomy).

          -  Subject who had a bacterial/viral infection within 2 weeks prior to the first dose of
             study medication.

          -  Subjects with current or prior neutropenia (eg, &lt;1.4 x 109 neutrophils /L).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5951164&amp;StudyName=Effect%20of%20Linezolid%20on%20Ex%20Vivo%20Neutrophil%20and%20Monocyte%20Function%20in%20Healthy%20Males%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 29, 2012</study_first_submitted>
  <study_first_submitted_qc>February 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2012</study_first_posted>
  <last_update_submitted>April 26, 2012</last_update_submitted>
  <last_update_submitted_qc>April 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

